nodes	percent_of_prediction	percent_of_DWPC	metapath
Nafarelin—Embolism arterial—Epirubicin—thyroid cancer	0.0473	0.0528	CcSEcCtD
Nafarelin—GNRHR—Hormone ligand-binding receptors—TSHR—thyroid cancer	0.0465	0.445	CbGpPWpGaD
Nafarelin—Embolism arterial—Doxorubicin—thyroid cancer	0.0438	0.0489	CcSEcCtD
Nafarelin—Transient ischaemic attack—Vandetanib—thyroid cancer	0.0271	0.0302	CcSEcCtD
Nafarelin—Ascites—Sorafenib—thyroid cancer	0.0203	0.0227	CcSEcCtD
Nafarelin—Interstitial lung disease—Vandetanib—thyroid cancer	0.0193	0.0216	CcSEcCtD
Nafarelin—Interstitial pneumonia—Sorafenib—thyroid cancer	0.0191	0.0213	CcSEcCtD
Nafarelin—Transient ischaemic attack—Sorafenib—thyroid cancer	0.0183	0.0204	CcSEcCtD
Nafarelin—Mucous membrane disorder—Epirubicin—thyroid cancer	0.017	0.019	CcSEcCtD
Nafarelin—Acne—Vandetanib—thyroid cancer	0.0162	0.0181	CcSEcCtD
Nafarelin—Mucous membrane disorder—Doxorubicin—thyroid cancer	0.0157	0.0175	CcSEcCtD
Nafarelin—Cystitis noninfective—Vandetanib—thyroid cancer	0.0134	0.0149	CcSEcCtD
Nafarelin—Cystitis—Vandetanib—thyroid cancer	0.0132	0.0147	CcSEcCtD
Nafarelin—Interstitial lung disease—Sorafenib—thyroid cancer	0.013	0.0145	CcSEcCtD
Nafarelin—Bladder pain—Vandetanib—thyroid cancer	0.0124	0.0138	CcSEcCtD
Nafarelin—Neoplasm—Vandetanib—thyroid cancer	0.0124	0.0138	CcSEcCtD
Nafarelin—Pleural effusion—Sorafenib—thyroid cancer	0.012	0.0134	CcSEcCtD
Nafarelin—GNRHR—Peptide GPCRs—TSHR—thyroid cancer	0.00937	0.0898	CbGpPWpGaD
Nafarelin—Dry skin—Vandetanib—thyroid cancer	0.00909	0.0102	CcSEcCtD
Nafarelin—Gastritis—Vandetanib—thyroid cancer	0.00878	0.0098	CcSEcCtD
Nafarelin—Neoplasm—Sorafenib—thyroid cancer	0.00834	0.00931	CcSEcCtD
Nafarelin—Gynaecomastia—Sorafenib—thyroid cancer	0.00825	0.00921	CcSEcCtD
Nafarelin—Dysuria—Vandetanib—thyroid cancer	0.00802	0.00895	CcSEcCtD
Nafarelin—Weight decreased—Vandetanib—thyroid cancer	0.00776	0.00866	CcSEcCtD
Nafarelin—Hepatic function abnormal—Sorafenib—thyroid cancer	0.00766	0.00855	CcSEcCtD
Nafarelin—Depression—Vandetanib—thyroid cancer	0.00762	0.00851	CcSEcCtD
Nafarelin—Ascites—Epirubicin—thyroid cancer	0.0075	0.00837	CcSEcCtD
Nafarelin—Conjunctivitis—Vandetanib—thyroid cancer	0.00743	0.0083	CcSEcCtD
Nafarelin—Epistaxis—Vandetanib—thyroid cancer	0.00721	0.00805	CcSEcCtD
Nafarelin—Sinusitis—Vandetanib—thyroid cancer	0.00717	0.00801	CcSEcCtD
Nafarelin—Ascites—Doxorubicin—thyroid cancer	0.00694	0.00775	CcSEcCtD
Nafarelin—Mood swings—Sorafenib—thyroid cancer	0.00634	0.00708	CcSEcCtD
Nafarelin—Dry skin—Sorafenib—thyroid cancer	0.00614	0.00685	CcSEcCtD
Nafarelin—Alopecia—Vandetanib—thyroid cancer	0.00607	0.00677	CcSEcCtD
Nafarelin—Mental disorder—Vandetanib—thyroid cancer	0.00601	0.00671	CcSEcCtD
Nafarelin—Malnutrition—Vandetanib—thyroid cancer	0.00598	0.00667	CcSEcCtD
Nafarelin—Gastritis—Sorafenib—thyroid cancer	0.00592	0.00661	CcSEcCtD
Nafarelin—Dysgeusia—Vandetanib—thyroid cancer	0.00585	0.00653	CcSEcCtD
Nafarelin—Vaginal discharge—Epirubicin—thyroid cancer	0.0056	0.00625	CcSEcCtD
Nafarelin—Myasthenia—Epirubicin—thyroid cancer	0.00542	0.00605	CcSEcCtD
Nafarelin—Weight decreased—Sorafenib—thyroid cancer	0.00523	0.00584	CcSEcCtD
Nafarelin—Vaginal discharge—Doxorubicin—thyroid cancer	0.00518	0.00579	CcSEcCtD
Nafarelin—Convulsion—Vandetanib—thyroid cancer	0.00518	0.00578	CcSEcCtD
Nafarelin—Chest pain—Vandetanib—thyroid cancer	0.00509	0.00568	CcSEcCtD
Nafarelin—Arthralgia—Vandetanib—thyroid cancer	0.00509	0.00568	CcSEcCtD
Nafarelin—Acute coronary syndrome—Sorafenib—thyroid cancer	0.00508	0.00568	CcSEcCtD
Nafarelin—Myocardial infarction—Sorafenib—thyroid cancer	0.00506	0.00565	CcSEcCtD
Nafarelin—Myasthenia—Doxorubicin—thyroid cancer	0.00502	0.0056	CcSEcCtD
Nafarelin—Seborrhoeic dermatitis—Epirubicin—thyroid cancer	0.005	0.00558	CcSEcCtD
Nafarelin—Oedema—Vandetanib—thyroid cancer	0.00488	0.00545	CcSEcCtD
Nafarelin—Epistaxis—Sorafenib—thyroid cancer	0.00487	0.00543	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—CALCB—thyroid cancer	0.00486	0.0466	CbGpPWpGaD
Nafarelin—Seborrhoeic dermatitis—Doxorubicin—thyroid cancer	0.00463	0.00516	CcSEcCtD
Nafarelin—Vaginal haemorrhage—Epirubicin—thyroid cancer	0.0046	0.00514	CcSEcCtD
Nafarelin—Pleural effusion—Epirubicin—thyroid cancer	0.00445	0.00497	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00444	0.00496	CcSEcCtD
Nafarelin—Insomnia—Vandetanib—thyroid cancer	0.00441	0.00492	CcSEcCtD
Nafarelin—Paraesthesia—Vandetanib—thyroid cancer	0.00438	0.00489	CcSEcCtD
Nafarelin—Dyspnoea—Vandetanib—thyroid cancer	0.00435	0.00485	CcSEcCtD
Nafarelin—Vaginal haemorrhage—Doxorubicin—thyroid cancer	0.00426	0.00476	CcSEcCtD
Nafarelin—Decreased appetite—Vandetanib—thyroid cancer	0.00424	0.00473	CcSEcCtD
Nafarelin—Constipation—Vandetanib—thyroid cancer	0.00417	0.00466	CcSEcCtD
Nafarelin—Pleural effusion—Doxorubicin—thyroid cancer	0.00412	0.0046	CcSEcCtD
Nafarelin—Alopecia—Sorafenib—thyroid cancer	0.00409	0.00457	CcSEcCtD
Nafarelin—Mental disorder—Sorafenib—thyroid cancer	0.00406	0.00453	CcSEcCtD
Nafarelin—Liver injury—Epirubicin—thyroid cancer	0.00405	0.00452	CcSEcCtD
Nafarelin—Malnutrition—Sorafenib—thyroid cancer	0.00403	0.0045	CcSEcCtD
Nafarelin—Dysgeusia—Sorafenib—thyroid cancer	0.00395	0.00441	CcSEcCtD
Nafarelin—Breast pain—Epirubicin—thyroid cancer	0.00391	0.00436	CcSEcCtD
Nafarelin—Liver injury—Doxorubicin—thyroid cancer	0.00375	0.00418	CcSEcCtD
Nafarelin—Oliguria—Epirubicin—thyroid cancer	0.0037	0.00413	CcSEcCtD
Nafarelin—Herpes simplex—Epirubicin—thyroid cancer	0.0037	0.00413	CcSEcCtD
Nafarelin—Breast pain—Doxorubicin—thyroid cancer	0.00361	0.00403	CcSEcCtD
Nafarelin—Asthenia—Vandetanib—thyroid cancer	0.0035	0.00391	CcSEcCtD
Nafarelin—Coordination abnormal—Epirubicin—thyroid cancer	0.00347	0.00387	CcSEcCtD
Nafarelin—Pruritus—Vandetanib—thyroid cancer	0.00345	0.00385	CcSEcCtD
Nafarelin—Myalgia—Sorafenib—thyroid cancer	0.00343	0.00383	CcSEcCtD
Nafarelin—Arthralgia—Sorafenib—thyroid cancer	0.00343	0.00383	CcSEcCtD
Nafarelin—Oliguria—Doxorubicin—thyroid cancer	0.00342	0.00382	CcSEcCtD
Nafarelin—Herpes simplex—Doxorubicin—thyroid cancer	0.00342	0.00382	CcSEcCtD
Nafarelin—Pulmonary embolism—Epirubicin—thyroid cancer	0.00341	0.0038	CcSEcCtD
Nafarelin—Diarrhoea—Vandetanib—thyroid cancer	0.00334	0.00373	CcSEcCtD
Nafarelin—Cystitis noninfective—Epirubicin—thyroid cancer	0.00333	0.00372	CcSEcCtD
Nafarelin—Cystitis—Epirubicin—thyroid cancer	0.00329	0.00367	CcSEcCtD
Nafarelin—Shock—Sorafenib—thyroid cancer	0.00324	0.00361	CcSEcCtD
Nafarelin—Dizziness—Vandetanib—thyroid cancer	0.00322	0.0036	CcSEcCtD
Nafarelin—Coordination abnormal—Doxorubicin—thyroid cancer	0.00321	0.00358	CcSEcCtD
Nafarelin—Pulmonary embolism—Doxorubicin—thyroid cancer	0.00315	0.00352	CcSEcCtD
Nafarelin—Anorexia—Sorafenib—thyroid cancer	0.00314	0.0035	CcSEcCtD
Nafarelin—Vomiting—Vandetanib—thyroid cancer	0.0031	0.00346	CcSEcCtD
Nafarelin—Rash maculo-papular—Epirubicin—thyroid cancer	0.0031	0.00346	CcSEcCtD
Nafarelin—Bladder pain—Epirubicin—thyroid cancer	0.00308	0.00344	CcSEcCtD
Nafarelin—Neoplasm—Epirubicin—thyroid cancer	0.00308	0.00344	CcSEcCtD
Nafarelin—Cystitis noninfective—Doxorubicin—thyroid cancer	0.00308	0.00344	CcSEcCtD
Nafarelin—Rash—Vandetanib—thyroid cancer	0.00307	0.00343	CcSEcCtD
Nafarelin—Dermatitis—Vandetanib—thyroid cancer	0.00307	0.00343	CcSEcCtD
Nafarelin—Headache—Vandetanib—thyroid cancer	0.00306	0.00341	CcSEcCtD
Nafarelin—Cystitis—Doxorubicin—thyroid cancer	0.00304	0.0034	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.003	0.00335	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00296	0.0283	CbGpPWpGaD
Nafarelin—Dyspnoea—Sorafenib—thyroid cancer	0.00293	0.00327	CcSEcCtD
Nafarelin—Nausea—Vandetanib—thyroid cancer	0.0029	0.00323	CcSEcCtD
Nafarelin—Rash maculo-papular—Doxorubicin—thyroid cancer	0.00287	0.0032	CcSEcCtD
Nafarelin—Decreased appetite—Sorafenib—thyroid cancer	0.00286	0.00319	CcSEcCtD
Nafarelin—Bladder pain—Doxorubicin—thyroid cancer	0.00285	0.00318	CcSEcCtD
Nafarelin—Neoplasm—Doxorubicin—thyroid cancer	0.00285	0.00318	CcSEcCtD
Nafarelin—Hepatic function abnormal—Epirubicin—thyroid cancer	0.00283	0.00316	CcSEcCtD
Nafarelin—Constipation—Sorafenib—thyroid cancer	0.00281	0.00314	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—CALCB—thyroid cancer	0.00275	0.0263	CbGpPWpGaD
Nafarelin—Eye pain—Epirubicin—thyroid cancer	0.00274	0.00306	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.00271	0.0259	CbGpPWpGaD
Nafarelin—Hot flush—Epirubicin—thyroid cancer	0.00264	0.00295	CcSEcCtD
Nafarelin—Increased appetite—Epirubicin—thyroid cancer	0.00263	0.00294	CcSEcCtD
Nafarelin—Menopausal symptoms—Epirubicin—thyroid cancer	0.00262	0.00293	CcSEcCtD
Nafarelin—Hepatic function abnormal—Doxorubicin—thyroid cancer	0.00262	0.00292	CcSEcCtD
Nafarelin—Urticaria—Sorafenib—thyroid cancer	0.00261	0.00292	CcSEcCtD
Nafarelin—Eye pain—Doxorubicin—thyroid cancer	0.00254	0.00283	CcSEcCtD
Nafarelin—Cerebrovascular accident—Epirubicin—thyroid cancer	0.00252	0.00282	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—CALCB—thyroid cancer	0.0025	0.0239	CbGpPWpGaD
Nafarelin—Hot flush—Doxorubicin—thyroid cancer	0.00245	0.00273	CcSEcCtD
Nafarelin—Increased appetite—Doxorubicin—thyroid cancer	0.00244	0.00272	CcSEcCtD
Nafarelin—Affect lability—Epirubicin—thyroid cancer	0.00243	0.00272	CcSEcCtD
Nafarelin—Menopausal symptoms—Doxorubicin—thyroid cancer	0.00243	0.00271	CcSEcCtD
Nafarelin—Asthenia—Sorafenib—thyroid cancer	0.00236	0.00264	CcSEcCtD
Nafarelin—Mood swings—Epirubicin—thyroid cancer	0.00234	0.00262	CcSEcCtD
Nafarelin—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.00234	0.00261	CcSEcCtD
Nafarelin—Pruritus—Sorafenib—thyroid cancer	0.00233	0.0026	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.0023	0.022	CbGpPWpGaD
Nafarelin—Dry skin—Epirubicin—thyroid cancer	0.00227	0.00253	CcSEcCtD
Nafarelin—Affect lability—Doxorubicin—thyroid cancer	0.00225	0.00252	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—TSHR—thyroid cancer	0.00225	0.0216	CbGpPWpGaD
Nafarelin—Diarrhoea—Sorafenib—thyroid cancer	0.00225	0.00251	CcSEcCtD
Nafarelin—Gastritis—Epirubicin—thyroid cancer	0.00219	0.00244	CcSEcCtD
Nafarelin—Muscular weakness—Epirubicin—thyroid cancer	0.00218	0.00244	CcSEcCtD
Nafarelin—Dizziness—Sorafenib—thyroid cancer	0.00218	0.00243	CcSEcCtD
Nafarelin—Mood swings—Doxorubicin—thyroid cancer	0.00217	0.00242	CcSEcCtD
Nafarelin—Abdominal distension—Epirubicin—thyroid cancer	0.00215	0.0024	CcSEcCtD
Nafarelin—Dry skin—Doxorubicin—thyroid cancer	0.0021	0.00234	CcSEcCtD
Nafarelin—Vomiting—Sorafenib—thyroid cancer	0.00209	0.00234	CcSEcCtD
Nafarelin—Rash—Sorafenib—thyroid cancer	0.00207	0.00232	CcSEcCtD
Nafarelin—Dermatitis—Sorafenib—thyroid cancer	0.00207	0.00231	CcSEcCtD
Nafarelin—Headache—Sorafenib—thyroid cancer	0.00206	0.0023	CcSEcCtD
Nafarelin—Gastritis—Doxorubicin—thyroid cancer	0.00203	0.00226	CcSEcCtD
Nafarelin—Muscular weakness—Doxorubicin—thyroid cancer	0.00202	0.00225	CcSEcCtD
Nafarelin—Dysuria—Epirubicin—thyroid cancer	0.002	0.00223	CcSEcCtD
Nafarelin—Abdominal distension—Doxorubicin—thyroid cancer	0.00199	0.00222	CcSEcCtD
Nafarelin—Nausea—Sorafenib—thyroid cancer	0.00195	0.00218	CcSEcCtD
Nafarelin—Weight increased—Epirubicin—thyroid cancer	0.00195	0.00217	CcSEcCtD
Nafarelin—Weight decreased—Epirubicin—thyroid cancer	0.00193	0.00216	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—PTCH1—thyroid cancer	0.00191	0.0183	CbGpPWpGaD
Nafarelin—Conjunctivitis—Epirubicin—thyroid cancer	0.00185	0.00207	CcSEcCtD
Nafarelin—Dysuria—Doxorubicin—thyroid cancer	0.00185	0.00207	CcSEcCtD
Nafarelin—Weight increased—Doxorubicin—thyroid cancer	0.0018	0.00201	CcSEcCtD
Nafarelin—Epistaxis—Epirubicin—thyroid cancer	0.0018	0.00201	CcSEcCtD
Nafarelin—Weight decreased—Doxorubicin—thyroid cancer	0.00179	0.002	CcSEcCtD
Nafarelin—Sinusitis—Epirubicin—thyroid cancer	0.00179	0.002	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—SST—thyroid cancer	0.00175	0.0168	CbGpPWpGaD
Nafarelin—Rhinitis—Epirubicin—thyroid cancer	0.00172	0.00192	CcSEcCtD
Nafarelin—Conjunctivitis—Doxorubicin—thyroid cancer	0.00171	0.00191	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—CALCA—thyroid cancer	0.00169	0.0161	CbGpPWpGaD
Nafarelin—Epistaxis—Doxorubicin—thyroid cancer	0.00166	0.00186	CcSEcCtD
Nafarelin—Sinusitis—Doxorubicin—thyroid cancer	0.00165	0.00185	CcSEcCtD
Nafarelin—Rhinitis—Doxorubicin—thyroid cancer	0.00159	0.00177	CcSEcCtD
Nafarelin—Alopecia—Epirubicin—thyroid cancer	0.00151	0.00169	CcSEcCtD
Nafarelin—Mental disorder—Epirubicin—thyroid cancer	0.0015	0.00167	CcSEcCtD
Nafarelin—Malnutrition—Epirubicin—thyroid cancer	0.00149	0.00166	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—CALCB—thyroid cancer	0.00147	0.0141	CbGpPWpGaD
Nafarelin—Tension—Epirubicin—thyroid cancer	0.00146	0.00163	CcSEcCtD
Nafarelin—Dysgeusia—Epirubicin—thyroid cancer	0.00146	0.00163	CcSEcCtD
Nafarelin—Nervousness—Epirubicin—thyroid cancer	0.00145	0.00162	CcSEcCtD
Nafarelin—Alopecia—Doxorubicin—thyroid cancer	0.0014	0.00156	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—TRIM33—thyroid cancer	0.0014	0.0134	CbGpPWpGaD
Nafarelin—Mental disorder—Doxorubicin—thyroid cancer	0.00139	0.00155	CcSEcCtD
Nafarelin—Malnutrition—Doxorubicin—thyroid cancer	0.00138	0.00154	CcSEcCtD
Nafarelin—Tension—Doxorubicin—thyroid cancer	0.00135	0.00151	CcSEcCtD
Nafarelin—Dysgeusia—Doxorubicin—thyroid cancer	0.00135	0.00151	CcSEcCtD
Nafarelin—Nervousness—Doxorubicin—thyroid cancer	0.00134	0.00149	CcSEcCtD
Nafarelin—Vertigo—Epirubicin—thyroid cancer	0.00134	0.00149	CcSEcCtD
Nafarelin—Palpitations—Epirubicin—thyroid cancer	0.00132	0.00147	CcSEcCtD
Nafarelin—Convulsion—Epirubicin—thyroid cancer	0.00129	0.00144	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—TSHR—thyroid cancer	0.00127	0.0122	CbGpPWpGaD
Nafarelin—Chest pain—Epirubicin—thyroid cancer	0.00127	0.00142	CcSEcCtD
Nafarelin—Arthralgia—Epirubicin—thyroid cancer	0.00127	0.00142	CcSEcCtD
Nafarelin—Myalgia—Epirubicin—thyroid cancer	0.00127	0.00142	CcSEcCtD
Nafarelin—Vertigo—Doxorubicin—thyroid cancer	0.00124	0.00138	CcSEcCtD
Nafarelin—Palpitations—Doxorubicin—thyroid cancer	0.00122	0.00136	CcSEcCtD
Nafarelin—Oedema—Epirubicin—thyroid cancer	0.00122	0.00136	CcSEcCtD
Nafarelin—Shock—Epirubicin—thyroid cancer	0.0012	0.00134	CcSEcCtD
Nafarelin—Convulsion—Doxorubicin—thyroid cancer	0.00119	0.00133	CcSEcCtD
Nafarelin—Hyperhidrosis—Epirubicin—thyroid cancer	0.00118	0.00131	CcSEcCtD
Nafarelin—Myalgia—Doxorubicin—thyroid cancer	0.00117	0.00131	CcSEcCtD
Nafarelin—Chest pain—Doxorubicin—thyroid cancer	0.00117	0.00131	CcSEcCtD
Nafarelin—Arthralgia—Doxorubicin—thyroid cancer	0.00117	0.00131	CcSEcCtD
Nafarelin—Anorexia—Epirubicin—thyroid cancer	0.00116	0.00129	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—TSHR—thyroid cancer	0.00116	0.0111	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PRKAR1A—thyroid cancer	0.00114	0.0109	CbGpPWpGaD
Nafarelin—Oedema—Doxorubicin—thyroid cancer	0.00112	0.00126	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00111	0.00124	CcSEcCtD
Nafarelin—Shock—Doxorubicin—thyroid cancer	0.00111	0.00124	CcSEcCtD
Nafarelin—Insomnia—Epirubicin—thyroid cancer	0.0011	0.00123	CcSEcCtD
Nafarelin—Paraesthesia—Epirubicin—thyroid cancer	0.00109	0.00122	CcSEcCtD
Nafarelin—Hyperhidrosis—Doxorubicin—thyroid cancer	0.00109	0.00121	CcSEcCtD
Nafarelin—Dyspnoea—Epirubicin—thyroid cancer	0.00108	0.00121	CcSEcCtD
Nafarelin—Anorexia—Doxorubicin—thyroid cancer	0.00107	0.0012	CcSEcCtD
Nafarelin—Decreased appetite—Epirubicin—thyroid cancer	0.00106	0.00118	CcSEcCtD
Nafarelin—Constipation—Epirubicin—thyroid cancer	0.00104	0.00116	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.00102	0.00114	CcSEcCtD
Nafarelin—Insomnia—Doxorubicin—thyroid cancer	0.00102	0.00114	CcSEcCtD
Nafarelin—Paraesthesia—Doxorubicin—thyroid cancer	0.00101	0.00113	CcSEcCtD
Nafarelin—Dyspnoea—Doxorubicin—thyroid cancer	0.001	0.00112	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—SST—thyroid cancer	0.000989	0.00948	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PTCH1—thyroid cancer	0.000982	0.00941	CbGpPWpGaD
Nafarelin—Decreased appetite—Doxorubicin—thyroid cancer	0.000978	0.00109	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.00097	0.0093	CbGpPWpGaD
Nafarelin—Urticaria—Epirubicin—thyroid cancer	0.000966	0.00108	CcSEcCtD
Nafarelin—Constipation—Doxorubicin—thyroid cancer	0.000962	0.00107	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—CALCA—thyroid cancer	0.000952	0.00913	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—TCF7L1—thyroid cancer	0.000932	0.00893	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—SST—thyroid cancer	0.000899	0.00861	CbGpPWpGaD
Nafarelin—Urticaria—Doxorubicin—thyroid cancer	0.000894	0.000998	CcSEcCtD
Nafarelin—Asthenia—Epirubicin—thyroid cancer	0.000872	0.000974	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—CALCA—thyroid cancer	0.000865	0.00829	CbGpPWpGaD
Nafarelin—Pruritus—Epirubicin—thyroid cancer	0.00086	0.00096	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.000835	0.008	CbGpPWpGaD
Nafarelin—Diarrhoea—Epirubicin—thyroid cancer	0.000832	0.000929	CcSEcCtD
Nafarelin—Asthenia—Doxorubicin—thyroid cancer	0.000807	0.000901	CcSEcCtD
Nafarelin—Dizziness—Epirubicin—thyroid cancer	0.000804	0.000898	CcSEcCtD
Nafarelin—Pruritus—Doxorubicin—thyroid cancer	0.000796	0.000889	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—CDK1—thyroid cancer	0.000783	0.0075	CbGpPWpGaD
Nafarelin—Vomiting—Epirubicin—thyroid cancer	0.000773	0.000863	CcSEcCtD
Nafarelin—Diarrhoea—Doxorubicin—thyroid cancer	0.00077	0.000859	CcSEcCtD
Nafarelin—Rash—Epirubicin—thyroid cancer	0.000767	0.000856	CcSEcCtD
Nafarelin—Dermatitis—Epirubicin—thyroid cancer	0.000766	0.000855	CcSEcCtD
Nafarelin—Headache—Epirubicin—thyroid cancer	0.000762	0.00085	CcSEcCtD
Nafarelin—Dizziness—Doxorubicin—thyroid cancer	0.000744	0.000831	CcSEcCtD
Nafarelin—Nausea—Epirubicin—thyroid cancer	0.000722	0.000806	CcSEcCtD
Nafarelin—Vomiting—Doxorubicin—thyroid cancer	0.000715	0.000799	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.00071	0.0068	CbGpPWpGaD
Nafarelin—Rash—Doxorubicin—thyroid cancer	0.000709	0.000792	CcSEcCtD
Nafarelin—Dermatitis—Doxorubicin—thyroid cancer	0.000709	0.000791	CcSEcCtD
Nafarelin—Headache—Doxorubicin—thyroid cancer	0.000705	0.000787	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—TSHR—thyroid cancer	0.000683	0.00654	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PRKAR1A—thyroid cancer	0.000671	0.00643	CbGpPWpGaD
Nafarelin—Nausea—Doxorubicin—thyroid cancer	0.000668	0.000746	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—MEN1—thyroid cancer	0.000642	0.00615	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PTCH1—thyroid cancer	0.00058	0.00556	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SST—thyroid cancer	0.000531	0.00509	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CALCA—thyroid cancer	0.000511	0.0049	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CDK1—thyroid cancer	0.000462	0.00443	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—NRG1—thyroid cancer	0.000371	0.00356	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—TERT—thyroid cancer	0.000333	0.00319	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HIF1A—thyroid cancer	0.000319	0.00305	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—NRAS—thyroid cancer	0.000281	0.00269	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—BRAF—thyroid cancer	0.000264	0.00253	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—KRAS—thyroid cancer	0.000242	0.00232	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—HRAS—thyroid cancer	0.000205	0.00197	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—AKT1—thyroid cancer	0.0002	0.00191	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CCND1—thyroid cancer	0.000193	0.00185	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PTEN—thyroid cancer	0.000186	0.00178	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—AKT1—thyroid cancer	0.000181	0.00174	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—NRAS—thyroid cancer	0.000166	0.00159	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—KRAS—thyroid cancer	0.000143	0.00137	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—TP53—thyroid cancer	0.000127	0.00122	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HRAS—thyroid cancer	0.000121	0.00116	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—AKT1—thyroid cancer	0.000107	0.00103	CbGpPWpGaD
